Novanta Inc. Reports Robust Financial Performance for Q4 and Full Year 2024

Novanta Inc. (Nasdaq: NOVT), a leading technology partner for medical and advanced technology equipment manufacturers, has announced its financial results for the fourth quarter and full year of 2024. The company showcased a strong operational performance, with revenue growth and notable increases in earnings, despite facing challenging economic conditions.

For the fourth quarter ending December 31, 2024, Novanta reported GAAP revenue of $238.1 million, marking a 12.5% increase or $26.5 million compared to the same quarter in 2023. This growth was significantly bolstered by acquisition activities, contributing 9.4% or $19.8 million to the revenue increase. However, the company faced a slight adverse impact of 0.3% or $0.5 million from foreign currency exchange rates.

GAAP operating income for the fourth quarter reached $26.7 million, up from $21.7 million in Q4 2023. The net income also saw a significant rise, totaling $16.5 million compared to $12.5 million in the prior year. This resulted in a GAAP diluted earnings per share (EPS) of $0.46, a notable increase from $0.35 in Q4 2023.

In terms of adjusted figures, the adjusted diluted EPS climbed to $0.76, reflecting a 21% increase year-over-year. The adjusted EBITDA also grew by 15%, reaching $52.1 million for the fourth quarter.

Novanta demonstrated impressive cash flow generation, with operating cash flow for the fourth quarter rising 58% to $61.6 million, up from $39.0 million in Q4 2023. This substantial increase highlights the company’s ability to manage its operations efficiently even amidst market challenges.

For the full year 2024, Novanta achieved GAAP revenue of $949.2 million, an increase of 7.7% or $67.6 million compared to 2023. The contributions from acquisitions were significant, accounting for 9.4% or $82.4 million of the year’s revenue. However, adverse foreign currency fluctuations slightly impacted the revenue by 0.1% or $0.5 million.

Despite the revenue growth, Novanta reported a 1.6% decrease in organic revenue growth for the full year, indicating challenges in achieving growth without the influence of acquisitions or currency changes. The GAAP operating income for the year stood at $110.6 million, slightly up from $110.5 million in 2023. However, net income experienced a decline to $64.1 million from $72.9 million in the previous year, resulting in a diluted EPS of $1.77, compared to $2.02 in 2023.

Adjusted operating income for the year reached $171.5 million, up from $156.6 million in 2023, while adjusted diluted EPS increased to $3.08, compared to $3.02 last year.

Matthijs Glastra, Chair and Chief Executive Officer of Novanta, expressed confidence in the company’s performance, stating, “Novanta achieved solid financial results for the full year 2024, effectively navigating a persistently challenging environment. We had strong operating performance, achieving above our expectations for Adjusted Gross Margins and Adjusted EBITDA, and also excellent cash flow generation, while also returning to organic growth in the Fourth Quarter.”

Glastra highlighted the successful launch of multiple new products during the year, which are expected to ramp up production in 2025, reinforcing Novanta’s strong fundamentals and growth strategy.

Novanta Inc.’s financial results for the fourth quarter and full year of 2024 reflect a company that is not only resilient but also strategically positioned for future growth. With strong revenue performance, effective cash flow management, and a commitment to innovation, Novanta remains a key player in the medical and advanced technology sectors. As the company looks forward to 2025, its focus on organic growth and product development will be crucial in maintaining its competitive edge.